Ainos (AIMD) Fireside chat summary
Event summary combining transcript, slides, and related documents.
Fireside chat summary
2 Feb, 2026Introduction and agenda
Discussion focused on the evolution of AI Nose from healthcare to a scalable AI perception platform, emphasizing its role in enabling machines to sense smell and its expansion into industrial and robotics sectors.
Background and experience of the speaker
The platform's foundation was built over 13 years in healthcare, calibrating the system for precision and reliability before expanding into industrial applications.
Current industry trends
AI is advancing by integrating new sensory inputs, with smell being the next frontier for machine perception.
Industrial environments, especially semiconductors and robotics, are increasingly adopting automated, sensor-driven solutions.
Partnerships and ecosystem development are critical for scaling in complex environments like semiconductor fabs.
Latest events from Ainos
- Secondary offering of 6.7M shares enables liquidity for stockholders, no proceeds to company.AIMD
Registration Filing16 Dec 2025 - Registration enables resale of 6.7M+ shares from various agreements and awards.AIMD
Registration Filing16 Dec 2025 - Shareholders will vote on auditor ratification, special stock awards, and meeting adjournment.AIMD
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, special stock awards, and key governance matters.AIMD
Proxy Filing2 Dec 2025 - Votes sought for auditor ratification and 2 million special stock awards at September 2024 meeting.AIMD
Proxy Filing2 Dec 2025 - AI Nose commercialization and cost reductions narrowed Q3 2025 net loss as revenue grew.AIMD
Q3 202513 Nov 2025 - AI Nose rollout drove first revenues, a $2.1M order, and positive gross margin despite wider losses.AIMD
Q2 202513 Aug 2025 - Q2 net loss rose to $3.2M as revenue dropped to zero and drug development accelerated.AIMD
Q2 202413 Jun 2025 - Q3 net loss rose 24% to $3.7M as Ainos pivots from COVID-19 kits to new clinical products.AIMD
Q3 202413 Jun 2025